Bexion Pharmaceuticals, Inc. Announces the Opening of a Pediatric Phase I Safety Study Using BXQ-350 in the Treatment of Rare CNS and Solid Tumors
FOR IMMEDIATE RELEASE Covington, KY ~ April 18, 2019 Bexion Pharmaceuticals, Inc., a clinical stage oncology company, announced today the initiation of an open-label Phase 1 Safety Study of BXQ-350. The first US site is Cincinnati Children’s Hospital Medical Center. This clinical trial will evaluate the safety of BXQ-350 and